TARS
Income statement / Annual
Last year (2025), Tarsus Pharmaceuticals Inc's total revenue was $451.36 M,
an increase of 146.71% from the previous year.
In 2025, Tarsus Pharmaceuticals Inc's net income was -$66.42 M.
See Tarsus Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$451.36 M |
$182.95 M |
$17.45 M |
$25.82 M |
$57.03 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$30.68 M
|
$12.83 M
|
$1.59 M
|
$955.00 K
|
$2.08 M
|
$246.00 K
|
$74.00 K
|
$1.00 K
|
| Gross Profit |
$420.68 M
|
$170.13 M
|
$15.85 M
|
$24.86 M
|
$54.95 M
|
-$246.00 K
|
-$74.00 K
|
-$1.00 K
|
| Gross Profit Ratio |
0.93
|
0.93
|
0.91
|
0.96
|
0.96
|
0
|
0
|
0
|
| Research and Development Expenses |
$64.32 M
|
$53.39 M
|
$50.31 M
|
$42.62 M
|
$41.71 M
|
$18.83 M
|
$3.16 M
|
$901.00 K
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$44.95 M
|
$25.40 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$427.32 M
|
$237.31 M
|
$108.70 M
|
$44.95 M
|
$25.40 M
|
$7.93 M
|
$1.06 M
|
$448.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$491.65 M
|
$290.70 M
|
$159.01 M
|
$87.57 M
|
$67.11 M
|
$26.74 M
|
$4.22 M
|
$1.35 M
|
| Cost And Expenses |
$522.33 M
|
$303.52 M
|
$160.61 M
|
$88.53 M
|
$69.18 M
|
$26.98 M
|
$4.30 M
|
$1.35 M
|
| Interest Income |
$15.75 M
|
$15.01 M
|
$10.34 M
|
$3.50 M
|
$36.00 K
|
$188.00 K
|
$40.00 K
|
$0.00
|
| Interest Expense |
$8.94 M
|
$7.45 M
|
$3.23 M
|
$2.06 M
|
$0.00
|
$188.00 K
|
$40.00 K
|
$0.00
|
| Depreciation & Amortization |
$1.82 M
|
$1.23 M
|
$877.00 K
|
$326.00 K
|
$312.00 K
|
$246.00 K
|
$74.00 K
|
$1.00 K
|
| EBITDA |
-$53.61 M |
-$106.48 M |
-$131.67 M |
-$59.71 M |
-$13.46 M |
-$26.56 M |
-$4.56 M |
-$1.32 M |
| EBITDA Ratio |
-0.12
|
-0.58
|
-7.55
|
-2.31
|
-0.24
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.16
|
-0.66
|
-8.21
|
-2.43
|
-0.21
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.61 M
|
$5.02 M
|
$7.27 M
|
$617.00 K
|
-$1.62 M
|
$173.00 K
|
-$371.00 K
|
$32.00 K
|
| Income Before Tax |
-$64.36 M
|
-$115.55 M
|
-$135.89 M
|
-$62.10 M
|
-$13.77 M
|
-$26.81 M
|
-$4.67 M
|
-$1.32 M
|
| Income Before Tax Ratio |
-0.14
|
-0.63
|
-7.79
|
-2.41
|
-0.24
|
0
|
0
|
0
|
| Income Tax Expense |
$2.06 M
|
$0.00
|
$0.00
|
-$4.00 K
|
$55.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
| Net Income |
-$66.42 M
|
-$115.55 M
|
-$135.89 M
|
-$62.09 M
|
-$13.83 M
|
-$26.81 M
|
-$4.67 M
|
-$1.32 M
|
| Net Income Ratio |
-0.15
|
-0.63
|
-7.79
|
-2.41
|
-0.24
|
0
|
0
|
0
|
| EPS |
-1.59 |
-3.07 |
-4.62 |
-2.52 |
-0.67 |
-1.32 |
-0.24 |
-0.31 |
| EPS Diluted |
-1.59 |
-3.07 |
-4.62 |
-2.52 |
-0.67 |
-1.32 |
-0.24 |
-0.31 |
| Weighted Average Shares Out |
$41.78 M
|
$37.60 M
|
$29.38 M
|
$24.62 M
|
$20.55 M
|
$20.32 M
|
$19.51 M
|
$4.29 M
|
| Weighted Average Shares Out Diluted |
$41.78 M
|
$37.60 M
|
$29.38 M
|
$24.62 M
|
$20.55 M
|
$20.32 M
|
$19.51 M
|
$4.29 M
|
| Link |
|
|
|
|
|
|
|
|
